{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-300219","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2022-12-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.599655+00:00","generated_at":"2026-06-21T08:04:25.169738+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Aadi Bioscience amends bylaws to revise director nomination procedures and conform to Delaware law","bullets":["Board amended and restated bylaws effective Dec 6, 2022, adding requirement for stockholders to deliver Rule 14a-19 compliance evidence 5 business days before meeting.","Revised procedures for stockholder director nominations and proposals to align with recent DGCL amendments.","Updated provisions regarding directors, Board committees, and officers; made ministerial and clarifications changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-300219","json":"https://secwatch.observer/filing/0001193125-22-300219.json","markdown":"https://secwatch.observer/filing/0001193125-22-300219.md","text":"https://secwatch.observer/filing/0001193125-22-300219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522300219/0001193125-22-300219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522300219/d431885d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:04:25.169738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50c5920881e9a4938e12173b16c0923c4ead1294","claim":"Whitehawk Therapeutics, Inc.: 董事会修订并重述了公司章程，以更新董事提名程序、股东会议程序并符合DGCL (effective 2022-12-06).","evidence_excerpt":"On December 6, 2022, the Board of Directors (the “Board”) of Aadi Bioscience, Inc. (the “Company”), acting upon the recommendation of the Nominating and Corporate Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422142/000119312522300219/0001193125-22-300219-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-06"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}